Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript

Waters reported 9% organic growth in 2Q, exceeding its 6%-8% guidance range, with orders again outpacing sales. Instrument and service revenue grew at high-single-digit rates, chemistry delivered double-digit growth, and underlying growth was 16% after adjusting for a prior-year Liberation Day-related pull-forward. Growth was broad-based, led by India at more than 20%, double-digit China growth, and double-digit pharmaceutical demand supported by replacement cycles and generics.

Analysis

WAT's setup is more attractive than the headline growth print suggests because the mix points to operating leverage: consumables and service growth can sustain gross margin and smooth the inherently lumpy instrument cycle. A broad replacement cycle at large pharma also favors Waters' installed-base economics over smaller, more transaction-dependent analytical-tool vendors. The relevant competitive read-through is constructive for A, TMO and DHR, but WAT should have the highest earnings sensitivity if replacement demand and chemistry attach rates persist.

The key near-term question is whether order momentum converts without a post-pull-forward air pocket. Over the next 1-3 months, investors will focus on book-to-bill, instrument backlog, China order quality, and whether management raises full-year organic-growth or margin expectations; a guidance increase would likely drive a further multiple rerating given WAT's historically less diversified revenue base. Over 6-18 months, India generic-drug capacity expansion and biopharma QC complexity support recurring chemistry and service demand, while China remains the largest source of volatility through funding, procurement and trade-policy risk.

Consensus may underappreciate the quality of a growth mix led by recurring revenue rather than simply extrapolating a cyclical instrument rebound. Conversely, the positive read-through to BDX is weak: the transcript does not establish an economic linkage to BDX, so treating this as a medtech demand signal would be a category error. The thesis is falsified if orders fall below revenue for two consecutive quarters, pharma replacement demand fails to broaden beyond large customers, or China growth decelerates sharply enough to force a full-year guide reset.

Key Decisions for Investors

• Initiate a 1-3 month long WAT / short A pair, sized modestly, if WAT holds post-conference gains into the next earnings window. WAT has greater upside to sustained replacement-cycle conversion and recurring-revenue mix; exit if WAT order growth trails revenue or if A shows materially stronger pharma/China order acceleration.
• Add to WAT only on confirmation of raised organic-growth or operating-margin guidance at the next earnings release; without valuation and consensus-estimate data, treat the current setup as a watch-to-buy rather than a full position. Target a 2:1 reward/risk structure using the pre-earnings low as the technical stop.
• Monitor DHR, TMO and A for corroborating commentary on pharma QC, chromatography consumables and China demand. Broad confirmation supports a sector basket; isolated WAT strength would instead favor the WAT/A relative-value expression and raise customer-concentration risk.
• Avoid using BDX as a sympathy long from this event. Reassess only if independently verified disclosures show meaningful demand linkage through laboratory, diagnostic, or bioprocess workflows.